What are the common antihypertensive treatments, their usual dosing ranges, and contraindications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Common Antihypertensive Treatments: Doses and Contraindications

For most patients with confirmed hypertension (BP ≥140/90 mmHg), initiate treatment with a two-drug combination from first-line classes: thiazide-type diuretics, ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), or long-acting dihydropyridine calcium channel blockers (CCBs), preferably as a single-pill combination. 1, 2

First-Line Antihypertensive Agents

Thiazide-Type Diuretics

Chlorthalidone:

  • Dose: 12.5-25 mg once daily 1
  • Key advantage: Longer half-life and more potent than hydrochlorothiazide on a mg-to-mg basis
  • Monitoring: Watch for hyponatremia, hypokalemia, hyperglycemia, hyperuricemia, and hypercalcemia
  • Contraindications: History of acute gout (unless patient is on urate-lowering therapy) 1

Hydrochlorothiazide (HCTZ):

  • Dose: 25-50 mg once daily 1
  • Note: Shorter-acting than chlorthalidone; recent pragmatic RCT showed no difference in MACE when switching from HCTZ to chlorthalidone in general population, though subgroup with ASCVD benefited more from chlorthalidone 1

Indapamide:

  • Dose: 1.25-2.5 mg once daily 1

ACE Inhibitors

Common agents with typical dosing 1:

  • Lisinopril: 10-40 mg once daily
  • Enalapril: 5-40 mg once or twice daily
  • Benazepril: 10-40 mg once or twice daily
  • Quinapril: 10-80 mg once or twice daily
  • Fosinopril: 10-40 mg once daily

Key contraindications:

  • Pregnancy (teratogenic)
  • Bilateral renal artery stenosis
  • History of angioedema
  • Never combine with ARB and/or renin inhibitor (Class 3 Harm recommendation - increases risk of hyperkalemia, hypotension, and renal dysfunction) 1

Monitoring: Serum creatinine and potassium within 2-4 weeks of initiation

Angiotensin Receptor Blockers (ARBs)

Common agents with typical dosing 1:

  • Losartan: 50-100 mg once daily
  • Valsartan: 80-320 mg once daily
  • Irbesartan: 150-300 mg once daily
  • Olmesartan: 20-40 mg once daily
  • Telmisartan: 40-80 mg once daily
  • Candesartan: 8-32 mg once daily

Contraindications: Same as ACEi (pregnancy, bilateral renal artery stenosis, combination with ACEi or renin inhibitor) 1, 2

Advantage over ACEi: Lower incidence of cough and angioedema

Long-Acting Dihydropyridine Calcium Channel Blockers

Amlodipine:

  • Dose: 2.5-10 mg once daily
  • Most commonly used CCB in combinations 1

Nifedipine (extended-release):

  • Dose: 30-90 mg once daily

Non-dihydropyridine CCBs (Verapamil, Diltiazem):

  • Verapamil SR: 120-480 mg once daily
  • Diltiazem SR: 120-360 mg once daily
  • Note: Useful for rate control but avoid in heart failure with reduced ejection fraction

Contraindications for CCBs:

  • Severe aortic stenosis
  • Heart failure with reduced ejection fraction (for non-dihydropyridines)
  • Severe gastroesophageal reflux disease (relative contraindication for dihydropyridines) 3

Common side effect: Peripheral edema (reduced when combined with ACEi or ARB) 1

Treatment Initiation Strategy

Stage 2 Hypertension (BP ≥140/90 mmHg)

Start with two-drug combination (Class 1 recommendation): 1, 2

  • Preferred combinations:
    • ACEi or ARB + thiazide-type diuretic
    • ACEi or ARB + dihydropyridine CCB
    • CCB + thiazide-type diuretic

Use single-pill combinations when possible to improve adherence 1, 2

Stage 1 Hypertension (BP 130-139/80-89 mmHg)

Monotherapy is reasonable with dose titration and sequential addition as needed 1

Exception: If high cardiovascular risk (≥7.5% 10-year risk), consider initiating treatment even at lower BP thresholds 4

Escalation to Three-Drug Therapy

If BP not controlled on two drugs, advance to: 1, 2

  • ACEi or ARB + dihydropyridine CCB + thiazide-type diuretic
  • Preferably as single-pill combination

Second-Line and Adjunctive Agents

Beta-Blockers

Use when compelling indications exist: 2

  • Post-myocardial infarction
  • Heart failure with reduced ejection fraction
  • Angina
  • Atrial fibrillation requiring rate control

Common agents:

  • Metoprolol succinate: 50-200 mg once daily
  • Carvedilol: 6.25-25 mg twice daily
  • Bisoprolol: 2.5-10 mg once daily
  • Atenolol: 25-100 mg once daily

Contraindications:

  • Severe asthma or COPD with bronchospasm 3
  • High-degree AV block (without pacemaker)
  • Severe bradycardia
  • Decompensated heart failure

Note: Safe in mild-to-moderate intermittent claudication but avoid in rest pain or limb ischemia 3

Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone:

  • Dose: 12.5-50 mg once daily
  • Use: Resistant hypertension (fourth-line agent)
  • Contraindications: Severe renal impairment (eGFR <30), hyperkalemia (K+ >5.0 mEq/L)
  • Monitoring: Potassium and creatinine closely

Eplerenone:

  • Dose: 50-100 mg once daily
  • Advantage: Less gynecomastia than spironolactone

Blood Pressure Targets

Target BP for most adults: <130/80 mmHg 1, 2

Intensive target (SBP <120 mmHg): Consider in high-risk patients when feasible and well-tolerated 1, 2

Target range per 2024 ESC guidelines: Systolic BP 120-129 mmHg in most adults 2

Important caveat: Individualize for patients with:

  • Age ≥85 years
  • Symptomatic orthostatic hypotension
  • Moderate-to-severe frailty
  • Limited life expectancy
  • Poor treatment tolerance

Use "as low as reasonably achievable" (ALARA) principle when intensive targets not tolerated 2

Critical Contraindications and Monitoring

Absolute Contraindications to Combination Therapy

Never combine ACEi + ARB + renin inhibitor (Class 3 Harm) 1, 2

  • Increases risk of hyperkalemia, hypotension, syncope, and acute kidney injury without additional benefit

Drug-Specific Monitoring Requirements

All RAS blockers (ACEi/ARB):

  • Baseline and follow-up creatinine and potassium
  • Acceptable creatinine increase: up to 30% from baseline
  • Hold if potassium >5.5 mEq/L

Thiazide diuretics:

  • Electrolytes (sodium, potassium)
  • Glucose and uric acid
  • More frequent monitoring in elderly

MRAs:

  • Potassium weekly initially, then monthly
  • Creatinine monitoring

Special Populations

Diabetes

  • Preferred agents: ACEi or ARB (renoprotective) 3
  • Target BP: <130/80 mmHg

Chronic Kidney Disease

  • Preferred agents: ACEi or ARB (slow progression)
  • Caution: Monitor creatinine and potassium closely

Post-Myocardial Infarction

  • Preferred agents: Beta-blocker + ACEi or ARB

Heart Failure with Reduced Ejection Fraction

  • Preferred agents: ACEi or ARB + beta-blocker + MRA + diuretic

Adherence Strategies

Evidence-based approaches to improve adherence: 1

  • Single-pill combinations over separate pills
  • Dose consolidation (once-daily dosing)
  • Medication synchronization
  • Home BP monitoring with feedback
  • Pharmacist education and coaching
  • Shared decision-making incorporating patient preferences

Timing of medication: Take at most convenient time for patient to establish habitual pattern; no evidence that bedtime dosing superior to morning dosing 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.